Feature | April 02, 2012

Small Change Makes Big Difference in Compliance Rates for Follow-Up Stress Tests

Scheduling Appointments Before Patients Leave ER Doubles Likelihood of Returning for Stress Test

April 2, 2012 — Stress tests are an important tool to help diagnose narrowed arteries in people who come to the emergency room (ER) with chest pain but are not confirmed as having a heart attack. Scheduling a follow-up exercise stress test before patients leave the ER more than doubles their likelihood of following through with the test, according to research presented at the American College of Cardiology (ACC) 61st Annual Scientific Session in Chicago.

The study, conducted in Australia, showed that among patients who were given an appointment for an exercise stress test before they left the ER, 70 percent actually underwent the test, compared with 31 percent of patients who were instructed to make the appointment themselves. Patients who were asked to make their own appointments also waited longer to take the test than those with pre-scheduled appointments (median time of 316 vs. just 77 hours, respectively).

“When patients were given a referral but were asked to make their own appointment, they often did not return for the stress test, despite the extra information the stress test can provide,” said Kevin Chung, M.D., University of Notre Dame in Fremantle, Australia, and the study’s lead investigator. “Our recommendation is that patients be given an appointment time for their test before they leave the ER. It’s even better to have the test before they leave the hospital.”

Exercise stress tests are one of several tools used to evaluate whether a person’s arteries are constricted by fatty build-up, which can increase the risk for a heart attack and other problems. The test monitors the electrical activity of the heart during exercise. Doctors use this information to decide whether a patient should be treated to reduce their risk of heart problems; failing to take the test puts patients at a higher risk of having an undiagnosed heart problem and not getting timely, appropriate care.

“In the ideal world, every patient who comes to the ER with chest pain would undergo a definitive test that gives 100 percent certainty of whether or not their arteries are normal,” Chung said. “While stress testing is not perfect, it provides very useful information. Any protocol that increases the proportion of patients having a stress test would help in patient follow-up.”

Previous studies have shown that patients who go to the ER with chest pain but are not confirmed as having a heart attack face a 2 to 3 percent chance of having a heart attack or other complication within 30 days. Current recommendations suggest these “intermediate risk” patients should undergo a stress test within 72 hours after discharge from the hospital.

The study also showed that patients with a clear understanding of the reason they were being asked to do an exercise stress test were more likely to attend their appointment. “From this we postulate that patient education regarding the rationale for the test will further improve compliance,” said Chung.

The researchers compared follow-up rates among 96 patients who were given an appointment for an exercise stress test before leaving the hospital with 121 patients who were asked to schedule their own appointments.

This study was self-funded by the University of Notre Dame in Fremantle, Australia; control group data were from a study funded by the Health Department of Western Australia.

For more information: www.acc.org.

Related Content

Biotronik, BioMonitor 2 implantable cardiac monitor, BioInsight clinical study, first patients enrolled
News | Implantable Cardiac Monitor (ICM)| January 20, 2017
Biotronik has enrolled the first patients in the BioInsight clinical study evaluating the safety and feasibility of...
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillators (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Cardiac Diagnostics| January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Overlay Init